KR20200083712A - Composition containing an mixed fermentation extract of rubus coreanus, soy bean and zanthoxylum schinifolium as an active ingredient and its use - Google Patents
Composition containing an mixed fermentation extract of rubus coreanus, soy bean and zanthoxylum schinifolium as an active ingredient and its use Download PDFInfo
- Publication number
- KR20200083712A KR20200083712A KR1020180171721A KR20180171721A KR20200083712A KR 20200083712 A KR20200083712 A KR 20200083712A KR 1020180171721 A KR1020180171721 A KR 1020180171721A KR 20180171721 A KR20180171721 A KR 20180171721A KR 20200083712 A KR20200083712 A KR 20200083712A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- complex
- soybean
- bokbunja
- active ingredient
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 115
- 244000068988 Glycine max Species 0.000 title claims abstract description 53
- 235000010469 Glycine max Nutrition 0.000 title claims abstract description 53
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 239000004480 active ingredient Substances 0.000 title claims abstract description 21
- 238000000855 fermentation Methods 0.000 title claims description 81
- 230000004151 fermentation Effects 0.000 title claims description 81
- 241001079064 Zanthoxylum schinifolium Species 0.000 title abstract description 5
- 241001618264 Rubus coreanus Species 0.000 title abstract 4
- 239000002537 cosmetic Substances 0.000 claims abstract description 26
- 230000002087 whitening effect Effects 0.000 claims abstract description 21
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 19
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 19
- 230000037303 wrinkles Effects 0.000 claims abstract description 17
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 16
- 230000003712 anti-aging effect Effects 0.000 claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 235000013402 health food Nutrition 0.000 claims abstract description 6
- 230000006872 improvement Effects 0.000 claims description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 10
- 241000191996 Pediococcus pentosaceus Species 0.000 claims description 7
- 239000004310 lactic acid Substances 0.000 claims description 5
- 235000014655 lactic acid Nutrition 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 2
- 239000000686 essence Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 26
- 239000002131 composite material Substances 0.000 abstract description 7
- 239000000463 material Substances 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 description 28
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 20
- 239000000523 sample Substances 0.000 description 17
- 244000302909 Piper aduncum Species 0.000 description 15
- 235000016761 Piper aduncum Nutrition 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 238000002835 absorbance Methods 0.000 description 12
- 102000003425 Tyrosinase Human genes 0.000 description 11
- 108060008724 Tyrosinase Proteins 0.000 description 11
- 235000006708 antioxidants Nutrition 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 10
- 230000008099 melanin synthesis Effects 0.000 description 10
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 150000008442 polyphenolic compounds Chemical class 0.000 description 8
- 235000013824 polyphenols Nutrition 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 7
- 230000009759 skin aging Effects 0.000 description 7
- -1 2-heptanone Chemical class 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 235000002566 Capsicum Nutrition 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 239000006002 Pepper Substances 0.000 description 5
- 235000017804 Piper guineense Nutrition 0.000 description 5
- 235000008184 Piper nigrum Nutrition 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 4
- 101710200814 Melanotropin alpha Proteins 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 4
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 3
- 240000008384 Capsicum annuum var. annuum Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000037319 collagen production Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 235000001497 healthy food Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 235000014594 pastries Nutrition 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- FLIACVVOZYBSBS-UHFFFAOYSA-N Methyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC FLIACVVOZYBSBS-UHFFFAOYSA-N 0.000 description 2
- 241000192001 Pediococcus Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 230000002292 Radical scavenging effect Effects 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229940074391 gallic acid Drugs 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- CATSNJVOTSVZJV-UHFFFAOYSA-N heptan-2-one Chemical compound CCCCCC(C)=O CATSNJVOTSVZJV-UHFFFAOYSA-N 0.000 description 2
- JARKCYVAAOWBJS-UHFFFAOYSA-N hexanal Chemical compound CCCCCC=O JARKCYVAAOWBJS-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000036564 melanin content Effects 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000006433 tumor necrosis factor production Effects 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 230000037373 wrinkle formation Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000221079 Euphorbia <genus> Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 1
- 101150004726 PFKP gene Proteins 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 241001092459 Rubus Species 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 229940092738 beeswax Drugs 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006388 chemical passivation reaction Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000003574 free electron Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000018791 negative regulation of catalytic activity Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/758—Zanthoxylum, e.g. pricklyash
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Birds (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 복분자, 대두 및 산초 복합 발효 추출물을 유효성분으로 함유하는 화장료 조성물에 대한 것이다. 보다 상세하게는, 본 발명은 항산화, 항염증, 피부 미백 및 주름 개선 효과를 나타내는 복분자, 대두 및 산초의 복합 추출물을 발효시켜 제조된 유효성분을 포함하는 화장료 조성물에 대한 것이다. The present invention relates to a cosmetic composition containing a complex fermented extract of bokbunja, soybean and sancho as an active ingredient. In more detail, the present invention relates to a cosmetic composition comprising an active ingredient prepared by fermenting a complex extract of bokbunja, soybean and sancho, which has antioxidant, anti-inflammatory, skin whitening and wrinkle improvement effects.
천연물로부터 생리활성 물질에 관한 연구가 활발히 진행되고 있으며, 질병에 대한 치료 및 예방제 또는 건강보조제로서 식물 자원이 널리 이용되고 있다.Researches on bioactive substances from natural products are being actively conducted, and plant resources are widely used as treatment and preventive agents or health supplements for diseases.
피부 노화는, 시간이 경과함에 따라 기관과 동반하여 피부의 구조와 기능이 지속적으로 감퇴되어지는 내인성 노화와 장기간에 걸친 태양 광선의 노출로 인한 피부 조직의 변화인 외인성 노화가 있다. 이러한 노화 과정으로 피부가 건조해지며, 주름이 생기고 피부는 탄력을 잃게 된다.Skin aging includes endogenous aging, in which the structure and function of the skin are continuously reduced along with organs over time, and exogenous aging, which is a change in skin tissue due to prolonged exposure to sunlight. Through this aging process, the skin becomes dry, wrinkles are formed, and the skin loses elasticity.
피부 노화에 관한 연구에서 가장 중요하게 다루어지는 것은 자유 라디칼(free radical)과 활성 산소종(reactive oxygen species)이다. 이들은 자연적으로 생체 내에서 만들어지기도 하지만 공해, 태양 자외선, 화학 산화제 및 미생물 등에 의해 발생된다. 이 때 발생된 자유 전자기나 활성 산소종은 피부 세포에 산화적 스트레스를 가하게 되고, 이러한 과정에서 생긴 물질은 멜라닌과 주름 생성의 원인물질로 여겨진다.The most important topics in skin aging research are free radicals and reactive oxygen species. They are naturally produced in vivo, but they are generated by pollution, solar ultraviolet rays, chemical oxidizing agents and microorganisms. The free electromagnetic or free radicals generated at this time exert oxidative stress on the skin cells, and the material produced in this process is considered to be the cause of melanin and wrinkles.
이때 발생되어진 자유 전자나 활성 산소종은 피부세포에 산화적 스트레스를 가하게 되고, 이러한 과정에서 생긴 물질은 멜라닌과 주름 생성의 원인 물질로 여겨진다.The free electrons or free radicals generated at this time exert oxidative stress on the skin cells, and the material produced in this process is considered to be the source of melanin and wrinkles.
이들 활성 산소종은 효소적, 비효소적 항산화제로 이루어진 피부 항산화 방어막을 붕괴시키고 생체 분자의 산화적 변형, 피부 장벽의 손상과 결합 조직인 콜라겐, 히아루론산 등의 사슬 절단 및 비정상적인 교차결합에 의한 주름생성 등 피부 노화를 가속시킨다.These free radicals disintegrate the skin antioxidant barrier made of enzymatic and non-enzymatic antioxidants, oxidative modification of biomolecules, damage to skin barrier and chain breakage of connective tissue such as collagen and hyaluronic acid, and wrinkle formation by abnormal cross-linking, etc. Accelerates skin aging
결과적으로 피부 노화 방지를 위해서는 과잉의 활성 산소종 생성을 억제하고 또한 생성된 활성 산소를 효율적으로 제거할 수 있어야 한다. 또한 피부 주름을 일으키는 효소들의 억제와 색소 침착을 진행하는 효소 활성 억제 등에 관한 연구가 필요하다. As a result, in order to prevent skin aging, it is necessary to suppress the generation of excess free radicals and to effectively remove the free radicals produced. In addition, studies on the inhibition of enzymes that cause skin wrinkles and the inhibition of enzyme activity that progresses pigmentation are needed.
한편, 멜라닌 생성 혹은 멜라노사이트의 증식에 의해 야기되는 색소 침착은 다양한 방법으로 억제가 가능하다. 일반적으로는 멜라닌 합성의 중요한 효소인 티로시나제(Tyrosinase) 활성 억제, 멜라노사이트의 기능 감소, 자동산화 반응의 억제를 통한 멜라닌 생성의 감소, 홍반과 같은 염증반응 억제등 다양한 경로를 이용할 수 있다.On the other hand, pigmentation caused by melanin production or proliferation of melanocytes can be suppressed in various ways. In general, various pathways such as inhibition of tyrosinase activity, an important enzyme for melanin synthesis, reduction of melanocyte function, reduction of melanin production through inhibition of an automatic oxidation reaction, and inhibition of inflammatory reactions such as erythema can be used.
결과적으로 피부노화 방지를 위해서는 과잉의 활성 산소종 생성을 억제하고 또한 생성된 활성산소를 효율적으로 제거할 수 있어야 하며, 피부의 주름을 일으키는 효소들의 억제, 색소침착을 진행하는 효소의 활성억제 등에 관한 연구가 필요하다. As a result, in order to prevent skin aging, it is necessary to suppress the generation of excess free radicals and to effectively remove the generated free radicals, and to suppress the enzymes that cause wrinkles on the skin and to inhibit the activity of enzymes that undergo pigmentation. Research is needed.
이와 관련하여, 피부노화 및 미백 관련해서 식물을 이용한 연구가 시행되어 왔다.In this regard, research using plants has been conducted in relation to skin aging and whitening.
복분자(Rubus coreauns)는 장미과(Rosaceae)에 속하는 복분자딸기의 열매를 일컫는 생약명으로, 복분자를 먹으면 요강이 소변 줄기에 뒤집어진다고 하여 붙은 이름이다. 복분자는 총당(17.3%), 환원당(8.6%), 조단백질(10.6%), 조회분(4.5%), 조지방(3.1%) 및 조섬유(3.9%)와 같은 성분을 함유하고 있으며, 아밀알코올을 포함하는 11종의 알코올류, 발레르산을 포함하는 산(acid)류, 헥산알을 포함하는 20종의 카보닐류, 2-헵타논을 포함하는 5종류의 하이드로카본, 및 메틸팔미트산염을 포함하는 3종류의 에스테르류의 향기성분을 함유하고 있다. 또한 폴리페놀(polyphenol)을 다량 함유하고 있어, 항암효과, 콜레스테롤의 저하, 고혈압이나 동맥경화의 억제, 과산화지질의 생성을 막아 노화의 예방, 혈청중 지질농도의 저하, 중성지질의 생성 억제에 의해 비만 방지 및 모세혈관의 저항력 증진 효과가 있는 것으로 보고되고 있다.Rubus coreauns is a medicinal name that refers to the fruit of a bokbunja strawberry belonging to the family Rosaceae. Bokbunja contains ingredients such as total sugar (17.3%), reduced sugar (8.6%), crude protein (10.6%), crude ash (4.5%), crude fat (3.1%) and crude fiber (3.9%), and contains amyl alcohol It contains 11 kinds of alcohols, acids containing valeric acid, 20 kinds of carbonyls including hexanal, 5 kinds of hydrocarbons including 2-heptanone, and methyl palmitate. Contains three types of ester fragrance components. In addition, since it contains a large amount of polyphenols, it has anti-cancer effects, lowering cholesterol, suppressing hypertension or arteriosclerosis, preventing the formation of lipid peroxide, preventing aging, lowering the lipid concentration in serum, and suppressing the production of neutral lipids. It has been reported to have an effect of preventing and enhancing capillary resistance.
대두(soybean)는 건물량 중 약 40%가 단백질로 구성되어 있고, 필수 아미노산이 풍부하여 우리나라에서는 전통적으로 단백질의 급원으로 사용되어 왔다. 다른 곡류의 단백질량이 보통 8~12%이고, 다른 콩과 식품의 단백질량이 20~30% 정도인 것을 고려하면, 대두의 단백질 구성은 매우 높은 수준이다. 또한, 대두에는 최근 생리활성 기능이 보고된 이소플라본(isoflavones) 및 피트산(phytic acid) 등이 풍부하며, 전 세계적으로 가공식품의 원료로 널리 사용되고 있다.Soybeans are traditionally used as a source of protein in Korea because about 40% of the amount of building is composed of protein and rich in essential amino acids. Considering that the amount of protein in other cereals is usually 8~12% and that of other legumes is about 20~30%, the protein composition of soybean is very high. In addition, soybean is rich in isoflavones and phytic acid, which have recently been reported to have bioactive functions, and are widely used as raw materials for processed foods worldwide.
산초(Zanthoxylum Schinifolium)는 쌍떡잎식물 쥐손이풀목 운향과의 낙엽관목으로 산지에서 자란다. 높이는 3m이고 잔가지는 가시가 있으며 붉은빛이 도는 갈색이다. 잎은 어긋나고 13-21개의 작은 잎으로 구성된 깃꼴겹잎이다. 작은 잎은 길이 1-5cm의 넓은 바소꼴이며 양끝이 좁고 가장자리에 물결 모양의 톱니와 더불어 투명한 유점이 있다. 산초는 잎을 따서 생으로 사용하거나, 열매껍질을 벗겨 말린 후 달이거나 농축해서 사용한다. 산초 열매는 소화불량, 식체, 위하수, 위확장, 구토, 이질, 설사, 신경쇠약, 기침, 회충 구제 등에 효능이 있다. 요리에는 후추와 비슷한 방법으로 사용된다.Sancho ( Zanthoxylum Schinifolium ) is a deciduous shrub with the dicotyledonous family of the Euphorbia musculus and grows in the mountains. The height is 3m, the twigs are thorny and reddish brown. The leaves are misaligned, composed of 13-21 small leaves. The small leaves are 1-5cm long, lanceolate, narrow at both ends, and have wavy teeth on the edges, with transparent spots. Sancho is used by picking leaves and using it raw or peeled and dried before being dried or concentrated. Sancho fruit is effective for indigestion, plant, stomach and sewage, gastric expansion, vomiting, dysentery, diarrhea, nervous breakdown, coughing, and roundworm remedies. It is used in a similar way to pepper.
이러한 복분자 발효 추출물의 심혈관 질환 치료 용도(특허문헌 1 참조), 대두 발효 추출물의 고지혈증 치료 용도(특허문헌 2 참조) 또는 산초 유래의 산초유를 포함하는 조성물의 아토피 피부 개선 용도(특허문헌 3 참조)에 대한 연구는 진행되었으나 항산화, 항노화, 항염증 및 미백 효능에 대한 연구, 또는 복분자, 대두 및 산초 복합 발효 추출물에 관련된 연구는 진행되지 않은 상황이다. Cardiovascular disease treatment use of the fermentation extract of the bimolecular molecule (refer to patent document 1), hyperlipidemia treatment use of soybean fermentation extract (refer to patent document 2), or atopy skin improvement use of a composition containing wild botanical oil derived from wild herb (see patent document 3) Studies have been conducted, but studies on antioxidant, anti-aging, anti-inflammatory and whitening efficacy, or studies related to bokbunja, soybean, and herbaceous complex fermentation extract have not been conducted.
이에 본 발명자들은 복분자, 대두 및 산초의 복합 발효 추출물을 이용한 연구를 수행하여 상기 복합 발효 추출물의 항산화, 항염증 및 미백 효능을 확인하여 본 발명을 완성하였다.Accordingly, the present inventors completed the present invention by confirming the antioxidant, anti-inflammatory, and whitening efficacy of the complex fermentation extract by conducting a study using the complex fermentation extract of bokbunja, soybean, and green pepper.
본 발명의 목적은 복분자, 대두 및 산초의 복합 발효 추출물을 유효성분으로 함유하는 화장료 조성물을 제공하기 위한 것이다.An object of the present invention is to provide a cosmetic composition containing a complex fermentation extract of bokbunja, soybean and sancho as an active ingredient.
본 발명의 다른 목적은 복분자, 대두 및 산초의 복합 추출물을 발효시켜 항산화, 항노화, 항염증 및 피부 미백 효과가 있는 유효 성분을 제조하는 방법 및 상기 유효성분을 포함하는 화장료 조성물을 제공하기 위한 것이다.Another object of the present invention is to provide a method for preparing an active ingredient having anti-oxidation, anti-aging, anti-inflammatory and skin whitening effects by fermenting a complex extract of bokbunja, soybean and sancho, and a cosmetic composition comprising the active ingredient .
본 발명의 또 다른 목적은 복분자, 대두 및 산초의 복합 발효 추출물을 유효성분으로 함유하는 항산화, 항노화, 항염증 및 피부 미백 효과가 있는 건강 식품을 제공하기 위한 것이다.Another object of the present invention is to provide a health food having antioxidant, anti-aging, anti-inflammatory, and skin whitening effects containing a complex fermented extract of bokbunja, soybean, and wild pepper as an active ingredient.
본 발명은 복분자, 대두 및 산초의 복합 발효 추출물을 유효성분으로 함유하는 화장료 조성물을 제공한다.The present invention provides a cosmetic composition containing a complex fermentation extract of bokbunja, soybean and sancho as an active ingredient.
상기 화장료 조성물은 항산화, 항노화, 항염증, 피부 미백 및 주름 개선 효과가 있을 수 있다.The cosmetic composition may have antioxidant, anti-aging, anti-inflammatory, skin whitening and wrinkle improvement effects.
상기 복분자, 대두 및 산초의 복합 추출물은 복분자, 대두 및 산초를 1:1:1 의 중량비로 혼합하여 제조할 수 있다. 복합 추출물 내 복분자, 대두 및 산초의 중량비가 1:1:1 범위를 벗어나는 경우, 발효시 발효 효율이 낮고 발효에 의해 제조된 복합 발효 추출물의 항염증 활성, 항산화 활성, 미백 효능 및 주름 개선 효능이 낮아서 비효율적이다.The complex extract of the bokbunja, soybean and sancho can be prepared by mixing bokbunja, soybean and sancho in a weight ratio of 1:1:1. When the weight ratio of bokbunja, soybean, and pepper in the complex extract is outside the 1:1:1 range, the fermentation efficiency during fermentation is low and the anti-inflammatory activity, antioxidant activity, whitening effect and wrinkle improvement effect of the complex fermentation extract prepared by fermentation Low and inefficient.
상기 유효성분은 복분자, 대두 및 산초의 복합 추출물을 유산균을 발효시켜 제조될 수 있고, 상기 유산균은 락토바실러스 균주 중 어느 하나일 수 있으며, 바람직하게는 페디오코커스(Pediococcus) 균주일 수 있으며, 가장 바람직하게는 페디오코커스 펜토사세우스(Pediococcus pentosaceus B1, 기탁번호 KACC 81067BP)이다. The active ingredient may be prepared by fermenting lactic acid bacteria with a complex extract of bokbunja, soybean, and sancho, and the lactic acid bacteria may be any of the Lactobacillus strains, preferably Pediococcus strains, Preferably Pediococcus pentosaceus B1, accession number KACC 81067BP).
상기 발효는 다양한 페디오코커스(Pediococcus) 균주를 복합 추출물 시료를 기준으로 균주액을 7 중량% 비율로 사용하여 실시할 수 있는데, 페디오코커스 펜토사세우스(Pediococcus pentosaceus B1, 기탁번호 KACC 81067BP) 균주를 사용하는 것이 바람직하다. 페디오코커스 펜토사세우스(Pediococcus pentosaceus B1, 기탁번호 KACC 81067BP) 이외의 균주를 사용하는 경우에는 발효 효율이 낮아서 비효율적이다. 또한, 균주액의 비율을 7 중량% 미만 또는 7 중량%를 초과하여 사용하면 발효 효율이 낮아서 비효율적이다.The fermentation may be carried out using various strains of Pediococcus strains based on a composite extract sample in a ratio of 7% by weight, Pediococcus pentosaceus B1, accession number KACC 81067BP It is preferred to use strains. When a strain other than Pediococcus pentosaceus B1 (Accession No. KACC 81067BP) is used, fermentation efficiency is low and thus inefficient. In addition, when the proportion of the strain solution is used in an amount of less than 7% by weight or more than 7% by weight, fermentation efficiency is low and thus inefficient.
상기 발효는 37℃에서 2 내지 7일간 실시할 수 있는데, 37℃ 보다 낮은 온도에서 발효하는 경우 발효 효율이 낮고, 2일 미만 또는 7일을 초과하여 발효하는 경우에는 발효 효율이 낮아서 비효율적이다.The fermentation can be carried out at 37°C for 2 to 7 days. When fermenting at a temperature lower than 37°C, the fermentation efficiency is low, and when fermenting for less than 2 days or for more than 7 days, the fermentation efficiency is low, which is inefficient.
본 발명에 따른 유효성분인 복분자, 대두 및 산초의 복합 발효 추출물은 화장료 조성물 전체에 대하여 50 내지 600 ㎍/mL로 포함될 수 있고, 보다 바람직하게는 100 내지 500 ㎍/mL로 포함될 수 있으며, 가장 바람직하게는 200 내지 300 ㎍/mL로 포함될 수 있다.The complex fermentation extract of the active ingredient according to the present invention, bokbunja, soybean and sancho, may be included at 50 to 600 µg/mL, more preferably 100 to 500 µg/mL, most preferably It may be included at 200 to 300 μg/mL.
상기 복분자, 대두 및 산초 복합 발효 추출물의 함량이 100 ㎍/mL 미만인 경우에는 미백 효능, 항산화 활성, 항노화 활성 및 항염증 활성이 나타나지 않을 수 있으며, 500 ㎍/mL 초과하는 경우에는 함유량 증가에 대한 효과 증대 정도가 미미할 수 있고 세포 독성이 강해서 경제적이지도 못하다.When the content of the complex molecule, soybean and wild-fermented fermentation extract is less than 100 µg/mL, the whitening efficacy, antioxidant activity, anti-aging activity and anti-inflammatory activity may not be exhibited, and when it exceeds 500 µg/mL, The degree of increase in effect may be negligible, and it is not economical due to strong cytotoxicity.
상기 화장료 조성물은 화장수, 에센스, 로션, 크림, 팩, 파운데이션, 젤, 연고 또는 스프레이로 구성된 군으로부터 선택될 수 있으나. 반드시 이로 한정되는 것은 아니다.The cosmetic composition may be selected from the group consisting of lotion, essence, lotion, cream, pack, foundation, gel, ointment or spray. It is not necessarily limited to this.
또한, 상기 화장료 조성물은 본 발명의 복분자, 대두 및 산초 복합 발효 추출물에 추가로 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항노화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉쇄제 및 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 화장품에 통상적으로 사용되는 임의의 다른 성분과 같은 화장품 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다.In addition, the cosmetic composition is a fat substance, an organic solvent, a solubilizer, a thickening agent and a gelling agent, an emollient, an anti-aging agent, a suspending agent, a stabilizing agent, a foaming agent, in addition to the complex fermented extract of the compound of the present invention, soybean and pepper ), fragrances, surfactants, water, ionic or nonionic emulsifiers, fillers, metal ion blockers and chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic actives, lipids It may contain adjuvants commonly used in the cosmetic field, such as vesicles or any other ingredients commonly used in cosmetics.
본 발명은 복분자, 대두 및 산초 복합 발효 추출물을 유효성분으로 함유하는 항산화, 항노화 효과 및 항염증 효과가 있는 약학적 조성물을 제공한다.The present invention provides a pharmaceutical composition having an antioxidant, anti-aging effect and anti-inflammatory effect, which contains a complex fermented extract of bokbunja, soybean and wild pepper as an active ingredient.
본 발명의 약학적 조성물은 통상적으로 사용되는 부형제, 붕해제, 감미제, 활택제, 향미제 등을 추가로 포함할 수 있으며, 통상적인 방법에 의해 정제, 캅셀제, 산제, 과립제, 현탁제, 유제, 시럽제, 기타 액제로 제형화될 수 있다. 구체적으로 본 발명의 약학적 조성물은 경구 투여용 제형, 예를 들면 정제, 트로치제(troches), 로젠지(lozenge), 수용성 또는 우성현탁액, 조제분말 또는 과립, 에멀젼, 하드 또는 소프트 캡슐, 시럽 또는 엘릭시르제(elixirs)로 제제화된다. 정제 및 캡슐 등의 제형으로 제제하기 위해 락토오스, 사카로오스, 솔비톨, 만니톨, 전분, 아밀로펙틴, 셀롤로오스 또는 젤라틴과 같은 결합제, 디칼슘 포스페이트와 같은 부형제, 옥수수 전분 또는 고구마 전분과 같은 붕해제, 스테아르산 마그네슘, 스테아르산 칼슘, 스테아릴푸마르산 나트륨 또는 폴리에틸렌글리콜 왁스와 같은 윤활유가 함유된다. 캡슐제형의 경우는 상기에서 언급한 물질 이외에도 지방유와 같은 액체 담체를 함유한다.The pharmaceutical composition of the present invention may further include commonly used excipients, disintegrants, sweeteners, lubricants, flavoring agents, and the like, and tablets, capsules, powders, granules, suspensions, emulsions, by conventional methods, It can be formulated as a syrup, other liquid. Specifically, the pharmaceutical composition of the present invention may be formulated for oral administration, for example, tablets, troches, lozenges, water-soluble or dominant suspensions, preparation powders or granules, emulsions, hard or soft capsules, syrups or It is formulated as elixirs. Binders such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose or gelatin, excipients such as dicalcium phosphate, disintegrants such as corn starch or sweet potato starch, stearic acid for formulation into tablets and capsules Contains lubricants such as magnesium, calcium stearate, sodium stearyl fumarate, or polyethylene glycol wax. In the case of capsule formulations, in addition to the above-mentioned substances, a liquid carrier such as fatty oil is contained.
또한, 본 발명의 약학적 조성물은 경구 또는 비경구 투여할 수 있으며, 비경구 투여시 피하주사, 정맥주사, 근육내 주사 또는 흉부내 주사 주입방식을 선택하는 것이 바람직하다. 비경구 투여용 제형으로 제제화하기 위해서는 본 발명의 센티페드그라스 추출물, 이의 분획물 또는 분획물로부터 분리한 활성분획을 안정제 또는 완충제와 함께 물에서 혼합하여 현탁액으로 제조하고 이를 앰플 또는 바이알의 단위 투여형으로 제제한다.In addition, the pharmaceutical composition of the present invention can be administered orally or parenterally, it is preferable to select a subcutaneous injection, intravenous injection, intramuscular injection or intrathoracic injection injection method when parenteral administration. In order to formulate a formulation for parenteral administration, the centifedgrass extract of the present invention, the fraction or its active fraction separated from the fraction is mixed with water with a stabilizer or buffer in a suspension to prepare a suspension and prepared as a unit dosage form of ampoules or vials do.
본 발명에 따른 유효성분의 투여량은 체내에서 활성성분의 흡수도, 불활성화율 및 배설속도, 환자의 연령, 성별 및 상태, 치료할 질병의 중증 정도에 따라 적절히 선택되나, 경구 투여제의 경우 일반적으로 성인에게 1일에 체중 1 ㎏당 본 발명의 추출물을 0.0001 ~ 500 ㎎의 양으로 1회 내지 수회 나누어 투여할 수 있으며, 0.001 ~ 100 ㎎의 양으로 투여하는 것이 바람직하다.The dosage of the active ingredient according to the present invention is appropriately selected according to the absorption of the active ingredient in the body, the rate of inactivation and excretion rate, the patient's age, sex and condition, and severity of the disease to be treated, but in the case of oral dosage forms, in general The extract of the present invention per kg of body weight per day can be administered to an adult once or several times in an amount of 0.0001 to 500 mg, preferably in an amount of 0.001 to 100 mg.
또한, 본 발명은 복분자, 대두 및 산초 복합 발효 추출물을 유효성분으로 함유하는 항산화, 항노화, 항염증, 피부 미백 및 주름 개선 효과가 있는 건강 식품을 제공한다.In addition, the present invention provides a healthy food having antioxidant, anti-aging, anti-inflammatory, skin whitening and wrinkle improvement effects containing the complex fermented extract of bokbunja, soybean and wild pepper as an active ingredient.
본 발명의 복분자, 대두 및 산초 복합 발효 추출물은 항산화, 항노화, 항염증, 피부 미백 및 주름 개선 효과가 우수하므로 건강 식품으로서 유용하게 사용될 수 있다.The compound of the present invention, the complex fermentation extract of soybean and wild pepper, has excellent antioxidant, anti-aging, anti-inflammatory, skin whitening and wrinkle improvement effects, and thus can be usefully used as a health food.
본 발명의 건강식품은 복분자, 대두 및 산초 복합 발효 추출물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다.The health food of the present invention may be added as a complex fermented extract of bokbunja, soybean, and herb, or may be used together with other foods or food ingredients, and may be suitably used according to a conventional method.
상기 식품의 종류에는 특별한 제한은 없다. 상기 복분자, 대두 및 산초 복합 발효 추출물을 첨가할 수 있는 식품의 예로는 육류, 소시지, 빵, 초콜릿, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코올음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.There are no particular restrictions on the type of food. Examples of foods to which the complex fermented soybean, soybean, and wild pepper complex fermentation extracts can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, and various soups , Beverages, teas, drinks, alcoholic beverages, and vitamin complexes, and includes all healthy foods in the usual sense.
본 발명의 건강 음료 조성물은 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토스, 슈크로스와 같은 디사카라이드, 및 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖당 일반적으로 약 0.01 ~0.04 g, 바람직하게는 약 0.02 ~ 0.03 g 이다.The healthy beverage composition of the present invention may contain various flavoring agents or natural carbohydrates, etc., as additional components, like a conventional beverage. The aforementioned natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As the sweetener, natural sweeteners such as taumatin and stevia extract, synthetic sweeteners such as saccharin and aspartame can be used. The proportion of the natural carbohydrate is generally about 0.01 to 0.04 g per 100 ml of the composition of the present invention, preferably about 0.02 to 0.03 g.
상기 외에 본 발명의 복분자, 대두 및 산초 복합 발효 추출물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다.In addition to the above, the complex fermented extract of the present invention, soybean and pepper, various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers , Preservatives, glycerin, alcohol, carbonic acid used in carbonated beverages, and the like.
그 밖에 본 발명의 복분자, 대두 및 산초 복합 발효 추출물은 천연 과일주스, 과일 주스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 혼합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 조성물 100 중량부당 0.01~0.1 중량부의 범위에서 선택되는 것이 일반적이다.In addition, the complex fermented extract of the compound of the present invention, soybean and pepper, may contain flesh for the production of natural fruit juice, fruit juice beverage and vegetable beverage. These ingredients can be used independently or in combination. The proportion of these additives is not critical, but is generally selected from 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
본 발명에 따라 제조된 복분자, 대두 및 산초의 복합 발효 추출물을 포함하는 조성물은 항산화, 항노화, 항염증, 피부 미백 및 주름 개선 효과가 우수하여 화장료 조성물, 약학적 조성물 및 건강 식품으로 이용할 수 있다.The composition comprising a complex fermented extract of bokbunja, soybean, and green pepper prepared according to the present invention has excellent antioxidant, anti-aging, anti-inflammatory, skin whitening and wrinkle improvement effects, and can be used as a cosmetic composition, pharmaceutical composition, and health food .
도 1은 복분자, 대두 및 산초의 복합 발효 추출물의 제조 과정을 나타낸 것이다.
도 2는 본 발명에서 사용한 발효 균주인 페디오코커스 펜토사세우스(Pediococcus pentosaceus) B1의 계통도에 관한 것이다.
도 3은 본 발명에 따른 복분자, 대두 및 산초의 복합 발효 추출물의 제조 과정에서 발효 전 및 발효 후의 항산화 활성을 측정한 결과에 관한 것이다.
도 4는 본 발명에 따른 복분자, 대두 및 산초의 복합 발효 추출물의 세포 독성을 측정한 결과에 관한 것이다.
도 5는 본 발명에 따른 복분자, 대두 및 산초의 복합 발효 추출물의 NO(Nitric Oxide) 저해 활성을 측정한 결과에 관한 것이다.
도 6은 본 발명에 따른 복분자, 대두 및 산초의 복합 발효 추출물의 항염증 저해 활성을 측정한 결과에 관한 것이다.
도 7은 본 발명에 따른 복분자, 대두 및 산초의 복합 발효 추출물의 티로시나아제 저해 활성을 측정한 결과에 관한 것이다.
도 8은 본 발명에 따른 복분자, 대두 및 산초의 복합 발효 추출물의 멜라닌 생성 억제 활성을 측정한 결과에 관한 것이다.
도 9는 본 발명에 따른 복분자, 대두 및 산초의 복합 발효 추출물의 콜라겐 생성 활성을 측정한 결과에 관한 것이다.Figure 1 shows the manufacturing process of the complex fermentation extract of bokbunja, soybean and sancho.
Figure 2 relates to the phylogenetic strain used in the present invention Pediococcus pentosaceus ( Pediococcus pentosaceus ) B1 is a schematic diagram.
Figure 3 relates to the results of measuring the antioxidant activity before and after fermentation in the process of preparing a complex fermentation extract of bokbunja, soybean and sancho according to the present invention.
Figure 4 relates to the results of measuring the cytotoxicity of the complex fermentation extract of bokbunja, soybean and wild pepper according to the present invention.
Figure 5 relates to the results of measuring the NO (Nitric Oxide) inhibitory activity of the complex fermentation extract of bokbunja, soybean and wild pepper according to the present invention.
Figure 6 relates to the results of measuring the anti-inflammatory inhibitory activity of the complex fermentation extract of bokbunja, soybean and wild pepper according to the present invention.
Figure 7 relates to the results of measuring the tyrosinase inhibitory activity of the complex fermentation extract of bokbunja, soybean and wild pepper according to the present invention.
Figure 8 relates to the results of measuring the melanin production inhibitory activity of the complex fermentation extract of bokbunja, soybean and sancho according to the present invention.
Figure 9 relates to the results of measuring the collagen production activity of the complex fermentation extract of bokbunja, soybean and wild pepper according to the present invention.
이하, 본 발명에 대하여 실시예 및 실험예를 통하여 보다 상세히 설명하나, 이들이 본 발명의 범위를 제한하는 것은 아니다.Hereinafter, the present invention will be described in more detail through examples and experimental examples, but they do not limit the scope of the present invention.
실시예 1. 복합 발효 추출물 제조Example 1. Preparation of complex fermentation extract
1.1 복합 추출물 제조1.1 Preparation of complex extracts
복분자 열매 및 대두를 수확하여 세척하고, 동결 건조 후 150 mesh 이상으로 파쇄하였다. 상기 파쇄된 건조 복분자 분말. 대두 분말 및 산초 열매를 200 mesh로 체를 쳐서 분말의 입자를 균일하게 통일한 후 1: 1: 1 중량비로 혼합한 후, 증류수를 첨가하고, pH 6.5로 조정하였다.After harvesting and washing the bokbunja fruit and soybean, lyophilized and crushed to 150 mesh or more. The crushed dry bokbunja powder. Sieve soybean powder and peppercorns were sifted with a 200 mesh to uniformly unify the particles of the powder, and then mixed in a 1: 1 weight ratio, distilled water was added, and the pH was adjusted to 6.5.
pH를 조절한 복합 혼합물은 121℃에서 15분간 멸균을 실시하여 복분자, 대두 및 산초의 복합 추출물 시료를 제조하였다(도 1 참조).The pH-controlled composite mixture was sterilized at 121° C. for 15 minutes to prepare a composite extract sample of bokbunja, soybean, and green pepper (see FIG. 1 ).
1.2 발효 균주 제조 1.2 Preparation of fermented strains
유산균 페디오코커스 펜토사세우스(Pediococcus pentosaceus) B1(도 2 및 기탁증 참조)을 MRS 배지에 접종하여 37℃에서 24시간 배양하였다. 배양된 균주는 3,000 rpm, 4oC 조건에서 15분간 원심분리를 실시하여 균체를 회수한 후, 상기 균체는 인산염 완충액(Phosphate buffer solution)으로 3회 세척을 실시하였다. 세척된 균체는 인산염 완충액을 사용하여 O.D(Optical Density) 1.0의 균주액을 제조하였다(도 1 참조).Lactic acid bacteria Pediococcus pentosaceus B1 (see FIG. 2 and deposit) was inoculated in MRS medium and cultured at 37° C. for 24 hours. The cultured strain was centrifuged at 3,000 rpm, 4 o C for 15 minutes to recover the cells, and the cells were washed three times with a phosphate buffer solution. For the washed cells, a strain solution of OD (Optical Density) 1.0 was prepared using a phosphate buffer (see FIG. 1).
1.3 복합 발효 추출물 제조1.3 Preparation of complex fermented extracts
실시예 1.1에 따른 복합 추출물 시료 전체를 기준으로 실시예 1.2에 따른 균주액을 5 중량% 비율로 접종하였다. The strain solution according to Example 1.2 was inoculated at a ratio of 5% by weight based on the entire sample of the composite extract according to Example 1.1.
접종 후에, 37℃에서 5일간 발효시켜 발효물을 제조하였다. 상기 발효물에 대하여 20% 에탄올을 추출 용매로 사용하여 5시간 추출을 실시하여 추출물을 제조하였다. 상기 추출물 내 고형물을 완전히 제거한 후 동결 건조를 통해 복합 발효 추출물을 완성하였다(도 1 참조). After inoculation, fermentation was prepared by fermenting at 37°C for 5 days. The fermented product was extracted by performing extraction for 5 hours using 20% ethanol as an extraction solvent. After completely removing the solids in the extract, the complex fermentation extract was completed through freeze drying (see FIG. 1 ).
실시예 2. 세포 독성 측정Example 2. Cytotoxicity measurement
실험에 사용된 세포에 대한 독성을 평가하기 위하여 MTT assay에 따라 세포생존율을 평가하였다. 계대 배양된 Raw 264.7 cell을 DMEM 배지를 사용하여 96-well plate에 1×105 cell/well씩 분주하여 37℃, 5% CO2 incubator에서 24 시간동안 배양하였다. 배양 후 세포 외 배지를 제거한 후 추출물을 농도별로 조성한 DMEM 용액을 100 ㎕ 처리한 후 37℃, 5% CO2 incubator에서 24 시간동안 반응시켰다. 대조군으로는 시료를 처리하지 않은 DMEM 용액을 처리하여 동일한 방법으로 실험을 진행하였다. 반응이 끝난 후 잔류 배지를 제거하고 5 ㎎/㎖ MTT (3-(4,5-dimethylthi azol-2-yl) -2,5-diphenyltetrazolium bromide) 용액을 well 당 50 ㎕ 씩 처리하여 37℃에서 4 h 반응시켰다. 이후 MTT 용액 제거하고 37℃에서 30 분간 건조과정을 진행하였으며, DMSO(dimethyl sulfoxide) 용액을 100 ㎕ 첨가하여 생성된 formazan을 완전히 용해시킨 후 microplate reader를 사용하여 550 nm 파장에서 흡광도를 측정하였다. 대조군으로는 시료를 처리하지 않은 세포의 흡광도를 분석하여 사용하였으며, 대조군의 흡광도를 100% 기준으로 처리구의 흡광도를 백분율로 계산하여 세포의 생존율을 환산하였다.In order to evaluate the toxicity to the cells used in the experiment, the cell viability was evaluated according to the MTT assay. Passage-cultured Raw 264.7 cells were dispensed 1×10 5 cells/well in 96-well plates using DMEM medium, and cultured for 24 hours in a 37°C, 5% CO 2 incubator. After incubation, the extracellular medium was removed, and then 100 µl of the DMEM solution composed of extracts by concentration was treated and reacted at 37° C. in a 5% CO 2 incubator for 24 hours. As a control, an experiment was conducted in the same way by treating a DMEM solution that was not treated with a sample. After the reaction was completed, the residual medium was removed and 50 µl/well of 5 mg/ml MTT (3-(4,5-dimethylthi azol-2-yl) -2,5-diphenyltetrazolium bromide) solution was treated at 37°C and 4 h reacted. Thereafter, the MTT solution was removed, and the drying process was performed at 37°C for 30 minutes, and 100 μl of DMSO (dimethyl sulfoxide) solution was added to completely dissolve the formazan, and absorbance was measured at a wavelength of 550 nm using a microplate reader. As a control, the absorbance of cells not treated with a sample was analyzed and used, and the absorbance of the treatment group was calculated as a percentage based on 100% of the control, and the cell viability was calculated.
(㎍/㎖)density
(Μg/ml)
(complex extract)Complex extract
(complex extract)
(Fermented complex extract)Fermentation complex extract
(Fermented complex extract)
세포 생존율을 측정한 결과, 복합 발효 추출물은 발효를 실시하지 않은 복합 추출물에 비해 세포 독성이 낮음을 확인하였다(표 1 및 도 3 참조).As a result of measuring cell viability, it was confirmed that the complex fermentation extract had lower cytotoxicity than the complex extract without fermentation (see Table 1 and FIG. 3).
실시예 3. 항산화 활성 측정Example 3. Measurement of antioxidant activity
3.1 DPPH 소거 활성3.1 DPPH scavenging activity
자유라디칼은 노화, 특히 피부 노화의 원인 물질로 알려진 것이다. 자유 라디칼 소거 활성 측정을 위해 메탄올을 사용하여 0.2 mM DPPH(2,2-Diphenyl-1-picryl-hydrazyl) 용액을 제조한 이후 각 농도별로 조성된 추출물과 혼합하였다. 혼합액을 37℃에서 30분간 반응시킨 후 UV-Vis spectrophotometer를 사용하여 517 nm 파장에서 흡광도를 분석하였다. 대조군으로는 추출물을 첨가하지 않은 DPPH 용액을 같은 조건에서 흡광도를 분석하여 결과 값을 계산하기 위한 식에 사용하였으며, 흡광도 값을 사용하여 DPPH radical scavenging 활성을 확인하기 위해 다음과 같은 식에 의해 측정하였다.Free radicals are known to cause aging, especially skin aging. To measure the free radical scavenging activity, a 0.2 mM DPPH (2,2-Diphenyl-1-picryl-hydrazyl) solution was prepared using methanol and then mixed with the extracts prepared for each concentration. After the mixture was reacted at 37°C for 30 minutes, absorbance was analyzed at a wavelength of 517 nm using a UV-Vis spectrophotometer. As a control, a DPPH solution without an extract was used in the formula for calculating the result value by analyzing the absorbance under the same conditions, and was measured by the following formula to confirm the DPPH radical scavenging activity using the absorbance value. .
DPPH radical scavenging 활성(%) = [(AbsDPPH - AbsSample)/AbsDPPH] × 100DPPH radical scavenging activity (%) = [(Abs DPPH -Abs Sample )/Abs DPPH ] × 100
여기서 Abssample은 시료 반응액의 흡광도이고, Absblank는 시료만의 흡광도, Abscontrol은 DPPH 용액의 흡광도이다. Here, Abssample is the absorbance of the sample reaction solution, Absblank is the absorbance of only the sample, and Abscontrol is the absorbance of the DPPH solution.
발효 과정 없이 제조된 복합 추출물 및 발효 과정에 의해 제조된 복합 발효 추출물의 DPPH 제거 활성을 측정한 결과, 발효 과정에 의해 제조된 복합 발효 추출물을 사용하는 경우에 DPPH 제거 활성이 더 높음을 확인하였다(도 4 참조).As a result of measuring the DPPH removal activity of the complex extract prepared without the fermentation process and the complex fermentation extract produced by the fermentation process, it was confirmed that the DPPH removal activity is higher when using the complex fermentation extract prepared by the fermentation process ( See Figure 4).
2.2 폴리페놀 함량 측정2.2 Measurement of polyphenol content
총 폴리페놀 함량 (total polyphenol content) 측정은 Folin-reagent가 페놀성 화합물에 의해 환원되어 몰리브덴 청색으로 발색되는 원리를 이용하여 함량을 정량하였다. 표준물질은 gallic acid (Sigma)를 사용하여 0-100 ㎍/mL 농도로 제조한 후 시료와 동일한 방법으로 분석하여 얻은 표준 검량선을 기준으로 시료의 폴리페놀 함량을 당량으로 계산하였다. 각 시료의 추출물은 60% 에탄올에 희석한 후 희석한 시료와 Folin-Ciocalteau’s phenol reagent 시약을 혼합하여 실온에서 차광된 상태로 1시간 동안 반응시켰다. 반응 후 96 well plate에 200 μL씩 분주한 후 765 nm에서 흡광도를 측정하고 건조 시료 1 g에서 용출되는 총 폴리페놀의 함량을 gallic acid 기준으로 폴리페놀 함량을 측정하였다. Measurement of total polyphenol content (total polyphenol content) was quantified using the principle that Folin-reagent is reduced by a phenolic compound to develop a molybdenum blue color. The standard was prepared using gallic acid (Sigma) at a concentration of 0-100 µg/mL, and the polyphenol content of the sample was calculated based on the standard calibration curve obtained by analyzing in the same manner as the sample. After extracting the extract of each sample in 60% ethanol, the diluted sample and Folin-Ciocalteau's phenol reagent reagent were mixed and reacted for 1 hour while being shaded at room temperature. After the reaction, 200 μL was dispensed into 96 well plates, and the absorbance was measured at 765 nm, and the total polyphenol content eluted from 1 g of the dried sample was measured based on gallic acid.
발효 과정 없이 제조된 복합 추출물 및 발효 과정에 의해 제조된 복합 발효 추출물의 총 폴리페놀 함량을 비교한 결과, 발효 과정에 의해 제조된 복합 발효 추출물을 사용하는 경우에 총 폴리페놀 함량이 더 높음을 확인하였다(도 4 참조).As a result of comparing the total polyphenol content of the complex extract prepared without the fermentation process and the complex fermentation extract produced by the fermentation process, it is confirmed that the total polyphenol content is higher when using the complex fermentation extract produced by the fermentation process (See FIG. 4).
실시예 4. 항염증 활성 측정Example 4. Measurement of anti-inflammatory activity
3.1 NO(Nitric Oxide) 저해 활성 측정3.1 Measurement of NO (Nitric Oxide) inhibitory activity
본 발명에 따른 복합 발효 추출물에 대하여, 주름 형성의 주요한 원인 중 하나인 염증 반응의 완화 효과를 NO(Nitric Oxide) 생성 억제 효능을 측정하여 평가하였다. For the complex fermentation extract according to the present invention, the effect of alleviating the inflammatory response, which is one of the main causes of wrinkle formation, was evaluated by measuring the effect of inhibiting NO (Nitric Oxide) production.
NO 생성 억제 효능을 측정하기 위해, RAW264.7 세포(mouse monocyte/macrophage-like cell)를 10% FBS가 첨가된 phenol red free DMEM 배지를 이용하여 24-well plate에 5×105 cell/well씩 분주하였다. 시료를 처리하고 48시간 경과 후 배양액을 취하여 Griess reagent와 1:1로 96-well plate에 처리한 후 상온에서 15분간 반응 한 다음 540 nm 파장에서 측정하였다.In order to measure the effect of inhibiting NO production, RAW264.7 cells (mouse monocyte/macrophage-like cells) were added to phenol red free DMEM medium containing 10% FBS at 5×10 5 cells/well in 24-well plates. I was busy. After processing the sample and taking the culture after 48 hours, the sample was treated 1:1 with Griess reagent, and then reacted for 15 minutes at room temperature, and then measured at a wavelength of 540 nm.
(㎍/㎖)density
(Μg/ml)
(complex extract)Complex extract
(complex extract)
(Fermented complex extract)Complex fermentation extract
(Fermented complex extract)
발효 과정 없이 제조된 복합 추출물 및 발효 과정에 의해 제조된 복합 발효 추출물의 NO 생성 억제 활성을 측정한 결과, 발효 과정에 의해 제조된 복합 발효 추출물을 다량 사용하는 경우에 NO 생성 억제 활성이 다소 높음을 확인하였다(표 2 및 도 5 참조). As a result of measuring the NO production inhibitory activity of the complex extract prepared without the fermentation process and the complex fermentation extract produced by the fermentation process, the NO production inhibitory activity is somewhat high when a large amount of the complex fermentation extract produced by the fermentation process is used. It was confirmed (see Table 2 and Figure 5).
3.2 Cytokine (TNF-α) 저해 활성 측정3.2 Cytokine (TNF-α) inhibitory activity measurement
본 발명에 따른 복합 발효 추출물에 있어서, 주름의 주요한 원인 중 하나인 염증 반응을 완화시키는 효과가 있는지 평가하기 위하여 염증성 반응 매개 물질인 TNF-α의 농도를 측정하여 복합 발효 추출물 처리 시 저해 활성을 확인하였다.In the complex fermentation extract according to the present invention, in order to evaluate whether there is an effect of alleviating the inflammatory response, which is one of the main causes of wrinkles, the concentration of the inflammatory reaction mediator TNF-α is measured to confirm the inhibitory activity during the treatment of the complex fermentation extract Did.
Raw 264.7 세포를 10% FBS, 1% antibiotics가 첨가된 DMEM 배지를 이용하여 24-well plate에 5×105 cell/well 씩 분주하고 37℃, 5% CO2 incubator에서 24시간 배양하였다. 배양 후 배지를 제거하고 TNF-α 유도를 위해 LPS 1ppm으로 조성한 농도별 추출물 용액을 500 ㎕ 처리한 뒤 24h 반응 시켰다. 이후 배양액을 취하여 TNF-α ELISA kit를 사용하여 TNF-α의 농도를 측정하였다.Raw 264.7 cells were dispensed at 5×10 5 cells/well in 24-well plates using DMEM medium with 10% FBS and 1% antibiotics, and cultured for 24 hours in a 37°C, 5% CO 2 incubator. After incubation, the medium was removed and 500 μl of the extract solution according to the concentration composed of 1 ppm of LPS for TNF-α induction was treated and reacted for 24 h. Then, the culture was taken and the concentration of TNF-α was measured using a TNF-α ELISA kit.
(㎍/㎖)density
(Μg/ml)
(TNF-α secretion inhibitory activity, %)TNF-α secretion inhibitory activity
(TNF-α secretion inhibitory activity, %)
(complex extract)Complex extract
(complex extract)
(Fermented complex extract)Fermentation complex extract
(Fermented complex extract)
발효 과정 없이 제조된 복합 추출물 및 발효 과정에 의해 제조된 복합 발효 추출물의 TNF-α 생성 억제 활성을 측정한 결과, 발효 과정에 의해 제조된 복합 발효 추출물을 사용하는 경우에 TNF-α 생성 억제 활성이 더 높음을 확인하였다(표 3 및 도 6 참조). As a result of measuring the inhibitory activity of TNF-α production of the complex extract prepared without the fermentation process and the complex fermentation extract produced by the fermentation process, the TNF-α production inhibitory activity was observed when using the complex fermentation extract prepared by the fermentation process. It was confirmed that it was higher (see Table 3 and Figure 6).
실시예 4. 미백 활성 측정Example 4. Measurement of whitening activity
4.1 티로시나아제(Tyrosinase) 저해활성 측정4.1 Measurement of tyrosinase inhibitory activity
본 발명에 따른 복합 발효 추출물의 미백 활성을 평가하기 위해, 티로시나아제 저해 활성을 측정하였다. Tyrosinase는 멜라닌을 합성하는 기작에서 작용하여 최종적으로 멜라닌 형성을 유도하는 효소 인자 중 하나이다. To evaluate the whitening activity of the complex fermentation extract according to the present invention, tyrosinase inhibitory activity was measured. Tyrosinase acts on a mechanism for synthesizing melanin and is one of the enzyme factors that induce melanin formation.
B16F10 melanoma를 이용하여 시료의 tyrosinase 저해 활성을 측정하였다. B16F10 melanoma을 6 well plate에 각 well 당 1×104 cells가 되도록 10% FBS가 포함된 각 cell의 배지를 사용하여 2 mL씩 분주하고 37℃, 5% CO2 incubator에서 24시간 배양하였다. 세포의 부착을 확인한 후, 시료를 농도별로 배지를 교환해주고, 1시간 후 100 nM α-MSH 자극제 처리 후, 37℃, 5% CO2 incubator에서 2일 간 배양하였다. 배지를 제거한 후 Triton X-100, 100 mM PMSF를 첨가한 Lysis buffer를 처리하고 10분 동안 15,000 rpm에서 원심분리 하였다. 이 후, 2% N,N-dimethyl formamide와 5 mM L-DOPA를 혼합한 mix buffer를 원심분리한 세포 상등액과 혼합하여 반응시키고 475 nm에서 흡광도를 측정하였다. tyrosinase의 저해 활성은 α-MSH만 처리한 군과 비교하여 백분율로 표시하였다.The tyrosinase inhibitory activity of the sample was measured using B16F10 melanoma. B16F10 melanoma was dispensed in 2 mL by using each cell medium containing 10% FBS in a 6 well plate to be 1×10 4 cells per well, and cultured for 24 hours in a 37°C, 5% CO 2 incubator. After confirming the adhesion of cells, the samples were exchanged for each concentration, and after 1 hour, after 100 nM α-MSH stimulator treatment, the cells were incubated for 2 days at 37°C and 5% CO 2 incubator. After removing the medium, the Lysis buffer to which Triton X-100 and 100 mM PMSF was added was treated and centrifuged at 15,000 rpm for 10 minutes. Thereafter, the mixture buffer mixed with 2% N,N-dimethyl formamide and 5 mM L-DOPA was mixed with the centrifuged cell supernatant to react and absorbance was measured at 475 nm. The inhibitory activity of tyrosinase was expressed as a percentage compared to the group treated with α-MSH only.
(㎍/㎖)density
(Μg/ml)
(tyrosinase inhibitory activity, %)Tyrosinase inhibitory activity
(tyrosinase inhibitory activity, %)
(complex extract)Complex extract
(complex extract)
(Fermented complex extract)Fermentation complex extract
(Fermented complex extract)
복합 발효 추출물의 미백 활성을 측정하기 위해 티로시나아제 저해 활성을 측정한 결과, 사용량에 따라 티로시나아제 저해 활성이 증가하는 것으로 확인하였다. 또한, 동일한 양에서는 발효 과정 없이 제조된 복합 추출물보다는 발효 과정에 의해 제조된 복합 발효 추출물의 효과가 더 높은 것으로 나타났다(표 4 및 도 7 참조).As a result of measuring the tyrosinase inhibitory activity to measure the whitening activity of the complex fermentation extract, it was confirmed that the tyrosinase inhibitory activity increased according to the amount of use. In addition, in the same amount, it was found that the effect of the complex fermentation extract prepared by the fermentation process is higher than that of the complex extract prepared without the fermentation process (see Table 4 and FIG. 7).
4.2 멜라닌(Melanin) 생성 억제활성 측정4.2 Measurement of melanin production inhibitory activity
본 발명에 따른 복합 발효 추출물의 미백 활성을 평가하기 위해, 멜라닌 생성 저해 저해 활성을 측정하였다.In order to evaluate the whitening activity of the complex fermentation extract according to the present invention, melanin production inhibition inhibitory activity was measured.
시료의 멜라닌 생합성에 미치는 영향을 알아보기 위하여 B16F10 melanoma를 6 well plate에 1×104이 되도록 분주하고 37℃, 5% CO2 incubator에서 24시간 배양하였다. 세포의 부착을 확인한 후, 멜라닌 생성을 촉진하기 위하여 10% FBS를 포함된 배지에 농도별로 첨가하여 4시간 배양하고, 이후 100 nM α-MSH 자극제를 처리하여 2 일 간 배양하였다. 배양액을 제거하고 PBS로 세척하고 scrapping하였다. 15,000 rpm에서 20 분간 원심분리 한 후, 상층액을 제거하고 pellet에 10% DMSO가 포함된 1 N NaOH 용액을 첨가하여 80℃에서 1시간 동안 용해하였으며, microplate reader를 이용하여 475 nm에서 흡광도를 측정하였다. 외부자극에 대한 melanoma cell 내 과생성 melanin에 대해 알아보기 위해 자극제로 100 nM α-MSH을 사용하였으며, 실험은 3회 이상 반복 실험하여 시료 무첨가구와 대조하여 그래프로 나타내었다.In order to examine the effect on the biosynthesis of melanin in the sample, B16F10 melanoma was dispensed to 1×10 4 in a 6 well plate and cultured for 24 hours in a 37°C, 5% CO 2 incubator. After confirming the adhesion of the cells, in order to promote melanin production, 10% FBS was added to the medium containing each concentration and cultured for 4 hours, and then treated with 100 nM α-MSH stimulant and cultured for 2 days. The culture was removed, washed with PBS and scrapped. After centrifugation at 15,000 rpm for 20 minutes, the supernatant was removed and 1 N NaOH solution containing 10% DMSO was added to the pellet to dissolve at 80°C for 1 hour, and absorbance was measured at 475 nm using a microplate reader. Did. 100 nM α-MSH was used as a stimulant to find out about over-produced melanin in melanoma cells for external stimulation. The experiment was repeated three or more times, and the graph was compared with the sample-free group.
(㎍/㎖)density
(Μg/ml)
(complex extract)Complex extract
(complex extract)
(Fermented complex extract)Complex fermentation extract
(Fermented complex extract)
복합 발효 추출물의 미백 활성을 측정하기 위해 멜라닌 합성 저해 활성을 측정한 결과, 복합 발효 추출물의 사용량에 따라 멜라닌 합성 저해 활성이 증가하는 것으로 확인하였다. 또한, 동일한 양에서는 발효 과정 없이 제조된 복합 추출물보다는 발효 과정에 의해 제조된 복합 발효 추출물의 효과가 더 높은 것으로 나타났다(도 9).As a result of measuring the melanin synthesis inhibitory activity to measure the whitening activity of the complex fermentation extract, it was confirmed that the melanin synthesis inhibitory activity increases according to the amount of the complex fermentation extract. In addition, in the same amount, it was found that the effect of the complex fermentation extract prepared by the fermentation process is higher than that of the complex extract prepared without the fermentation process (FIG. 9).
실시예 5. 주름 개선 활성 측정Example 5. Measurement of wrinkle improvement activity
본 발명에 따른 복합 발효 추출물의 주름 개선 활성을 평가하기 위해, 콜라겐 생성 활성을 측정하였다.In order to evaluate the wrinkle improvement activity of the complex fermentation extract according to the present invention, collagen production activity was measured.
human fibroblast 세포를 이용하여 시료의 콜라겐 생성에 미치는 영향을 확인하였다. Fibroblast 세포를 Dermal fibroblast growth medium 배지를 이용하여 96-well plate에 well 당 1×104씩 분주하고 37℃, 5% CO2 incubator에서 24시간 배양하여 세포를 부착하였다. 이후 추출물 농도별로 조성한 배지 용액을 처리하고 24 h 후 세포 배양액에 생성된 콜라겐의 농도를 Procollagen Type Ⅰ C-peptide EIA kit를 사용하여 측정하였다.Using human fibroblast cells, the effect on the collagen production of the sample was confirmed. Fibroblast cells were dispensed 1×10 4 per well into a 96-well plate using Dermal fibroblast growth medium medium, and cultured for 24 hours in a 37°C, 5% CO 2 incubator to attach the cells. Subsequently, the medium solution prepared for each extract concentration was treated, and after 24 h, the concentration of collagen generated in the cell culture was measured using a Procollagen Type I C-peptide EIA kit.
발효 과정 없이 제조된 복합 추출물보다는 발효 과정에 의해 제조된 복합 발효 추출물의 효과가 더 높은 것으로 나타났다(도 9).It was found that the effect of the complex fermentation extract prepared by the fermentation process was higher than that of the complex extract prepared without the fermentation process (FIG. 9 ).
실시예 6. 화장료 조성물의 제조Example 6. Preparation of cosmetic composition
하기 표 6에 나타낸 조건(단위, 중량%)으로 화장료 조성물을 제조하였다.A cosmetic composition was prepared under the conditions shown in Table 6 (unit, weight percent).
실시예 7. 추출물이 함유된 약제 제조Example 7. Preparation of the drug containing the extract
하기 표 7에 나타낸 조건(단위, 중량%)으로 약제 조성물을 제조하였다.The pharmaceutical composition was prepared under the conditions (unit, weight%) shown in Table 7 below.
실시예 8. 추출물이 함유된 건강 식품 제조Example 8. Preparation of healthy food containing extracts
복분자, 대두 및 산초의 복합 발효 추출물 25 중량부를 과자 반죽에 첨가하고, 이 혼합물을 이용하여 빵, 케이크, 쿠키, 크래커 및 면류를 제조하였다(표 8 참조).25 parts by weight of the complex fermented extract of bokbunja, soybean and sancho were added to the pastry dough, and bread, cake, cookies, crackers and noodles were prepared using this mixture (see Table 8).
본 발명의 단순한 변형 내지 변경은 이 분야의 통상의 지식을 가진 자에 의하여 용이하게 실시될 수 있으며, 이러한 변형이나 변경은 모두 본 발명의 영역에 포함되는 것으로 볼 수 있다.Simple modifications or changes of the present invention can be easily carried out by those skilled in the art, and all such modifications or changes can be considered to be included in the scope of the present invention.
기탁기관명 : 농업생명공학연구원Depository name: Institute for Agricultural Biotechnology
수탁번호 : KACC81067Accession number: KACC81067
수탁일자 : 20171124Date of Deposit: 20171124
Claims (10)
A cosmetic composition containing a complex fermented extract of bokbunja, soybean and sancho as an active ingredient.
According to claim 1, wherein the complex extract of bokbunja, soybean and sancho, characterized in that the bokbunja, soybean and sancho are mixed in a weight ratio of 1: 1, cosmetic composition.
상기 유효성분은 유산균을 사용하여 복분자, 대두 및 산초의 복합 추출물을 발효시켜 제조된 것을 특징으로 하는, 화장료 조성물.
According to claim 1,
The active ingredient is produced by fermenting a complex extract of bokbunja, soybean, and sancho using lactic acid bacteria, cosmetic composition.
상기 유산균은 Pediococcus pentosaceus B1(KACC 81067BP)인 것을 특징으로 하는, 화장료 조성물.
According to claim 3,
The lactic acid bacteria is Pediococcus pentosaceus B1 (KACC 81067BP), cosmetic composition.
상기 발효는 37℃에서 2 내지 7일간 실시하는 것을 특징으로 하는, 화장료 조성물.
According to claim 3,
The fermentation is characterized in that carried out for 2 to 7 days at 37 ℃, cosmetic composition.
상기 화장료 조성물은 항산화, 항노화, 항염증, 피부 미백 및 주름 개선 용도인 것을 특징으로 하는, 화장료 조성물.
According to claim 1,
The cosmetic composition is characterized in that the antioxidant, anti-aging, anti-inflammatory, skin whitening and wrinkle improvement purposes, cosmetic composition.
상기 유효성분은 100 내지 500㎍/mL을 포함하는 것을 특징으로 하는, 화장료 조성물.
According to claim 1,
The active ingredient is characterized in that it contains 100 to 500㎍ / mL, cosmetic composition.
상기 화장료 조성물은 화장수, 에센스, 로션, 크림, 팩, 파운데이션, 젤, 연고 및 스프레이로 구성된 군으로부터 선택된 어느 하나의 제형을 갖는 것인 화장료 조성물.
According to claim 1,
The cosmetic composition is a cosmetic composition having any one formulation selected from the group consisting of lotion, essence, lotion, cream, pack, foundation, gel, ointment and spray.
Antioxidant, anti-aging and anti-inflammatory pharmaceutical composition containing a complex fermented extract of bokbunja, soybean and sancho as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180171721A KR20200083712A (en) | 2018-12-28 | 2018-12-28 | Composition containing an mixed fermentation extract of rubus coreanus, soy bean and zanthoxylum schinifolium as an active ingredient and its use |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180171721A KR20200083712A (en) | 2018-12-28 | 2018-12-28 | Composition containing an mixed fermentation extract of rubus coreanus, soy bean and zanthoxylum schinifolium as an active ingredient and its use |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20200083712A true KR20200083712A (en) | 2020-07-09 |
Family
ID=71602253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020180171721A KR20200083712A (en) | 2018-12-28 | 2018-12-28 | Composition containing an mixed fermentation extract of rubus coreanus, soy bean and zanthoxylum schinifolium as an active ingredient and its use |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20200083712A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220077461A (en) | 2020-12-02 | 2022-06-09 | 천년산초의령 영농조합법인 | Sancho lotion manufacturing method |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100656241B1 (en) | 2004-09-10 | 2006-12-11 | 롯데제과주식회사 | The extract of Korean fermented soybean with inhibitory effect on hyperlipemia and platelet aggregation, and their composition |
KR100862610B1 (en) | 2006-11-17 | 2008-10-09 | 전라북도 고창군 | Composition for preventing or treating cardiovascular diseases comprising an extract of rubus coreanum fermentation as active ingredient |
KR101056475B1 (en) | 2008-10-17 | 2011-08-11 | 한국국제대학교 산학협력단 | Cosmetic composition for improving atopic skin containing acetic acid |
-
2018
- 2018-12-28 KR KR1020180171721A patent/KR20200083712A/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100656241B1 (en) | 2004-09-10 | 2006-12-11 | 롯데제과주식회사 | The extract of Korean fermented soybean with inhibitory effect on hyperlipemia and platelet aggregation, and their composition |
KR100862610B1 (en) | 2006-11-17 | 2008-10-09 | 전라북도 고창군 | Composition for preventing or treating cardiovascular diseases comprising an extract of rubus coreanum fermentation as active ingredient |
KR101056475B1 (en) | 2008-10-17 | 2011-08-11 | 한국국제대학교 산학협력단 | Cosmetic composition for improving atopic skin containing acetic acid |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220077461A (en) | 2020-12-02 | 2022-06-09 | 천년산초의령 영농조합법인 | Sancho lotion manufacturing method |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20090083082A (en) | Compositions comprising fermentative extract of orchidaceae for improving functions of skin | |
KR20200083710A (en) | Composition containing an fermentation extract of zanthoxylum schinifolium as an active ingredient and its use | |
KR20220136107A (en) | Method for producing fermented product by lactic acid bacteria of Aloe with increased effective component content and postbioics products containing the same | |
KR20190090363A (en) | Cosmetic composition comprising mixture of fermented extract of Cirsium japonicum and Moringa oleifera | |
KR20110040363A (en) | A composition for skin whitening comprising extracts or fractions of eremochloa ophiuroides as an active ingredient | |
KR101004361B1 (en) | The extracts and fractions of Hippophae rhamnoides L. | |
KR20200083712A (en) | Composition containing an mixed fermentation extract of rubus coreanus, soy bean and zanthoxylum schinifolium as an active ingredient and its use | |
KR102275055B1 (en) | Composition comprising scutellaria alpina extract | |
KR101895572B1 (en) | Antioxidant composition comprising uldavioside A | |
KR101889331B1 (en) | A composition having anti-oxidation, anti-inflammation or anti-bacterial activity comprising Acanthopanax koreanum Nakai stem extracts, fractions thereof or compounds isolated therefrom as an active ingredient | |
KR102537844B1 (en) | Composition with antibacterial, antioxidant, and anti-inflammatory activity containing ingredients converted to kimchi lactic acid bacteria and breast lactic acid bacteria in marigold extract | |
KR101063351B1 (en) | The extracts and fractions of Hippophae rhamnoides L. | |
KR102342814B1 (en) | Composition containing an fermented extract of protaetia brevitarsis seulensis as an active ingredient and manufacturing the same | |
KR20180024481A (en) | Method for preparing apricot extract, the apricot extract prepared therefrom, and skin care or cosmetic composition comprising the apricot extract | |
KR20120073720A (en) | Composition for antiaging comprising the extract of dipterocarpus obtusifolius teijsm. ex miq. as an active ingredient | |
KR101797843B1 (en) | A composition having anti-inflammation or anti-bacterial activity comprising Acanthopanax koreanum Nakai stem extracts, fractions thereof or compounds isolated therefrom as an active ingredient | |
KR20160091037A (en) | Composition comprising gooseberry or glutathione | |
KR100921971B1 (en) | A composition comprising Chamaenerion angustifolium extract as an active ingredient | |
KR20200101114A (en) | Food composition comprising Chrysanthemum zawadskii var extract | |
KR102453568B1 (en) | Composition for moisturizing and anti-inflammation comprising fermented Codium fragile extract fermented by inoculating Bacillus safensis strain | |
KR102355138B1 (en) | Composition for whitening or anti-wrinkle of the skin comprising fermentated ziziphus jujuba seed as effective component | |
KR101007001B1 (en) | The extracts and fractions of Hippophae rhamnoides L. | |
KR101425560B1 (en) | Composition for antioxidant comprising extracts or its fractions of Elaeocarpus petiolatus as an active ingredient | |
KR102216618B1 (en) | Fermentation method of lactic acid bacteria using artichoke and its use | |
KR102185438B1 (en) | Antioxidant composition containing femented mulberry extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E601 | Decision to refuse application |